25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AKTX (Akari Therapeutics PLC) Stock Analysis
Buy, Hold or Sell?

Let's analyze Akari Therapeutics PLC together

I guess you are interested in Akari Therapeutics PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Akari Therapeutics PLC’s Financial Insights
  • 📈 Technical Analysis (TA) – Akari Therapeutics PLC’s Price Targets

I'm going to help you getting a better view of Akari Therapeutics PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Akari Therapeutics PLC

I send you an email if I find something interesting about Akari Therapeutics PLC.

1. Quick Overview

1.1. Quick analysis of Akari Therapeutics PLC (30 sec.)










1.2. What can you expect buying and holding a share of Akari Therapeutics PLC? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.68
Expected worth in 1 year
$1.46
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$0.79
Return On Investment
69.5%

For what price can you sell your share?

Current Price per Share
$1.13
Expected price per share
$1.08 - $1.42
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Akari Therapeutics PLC (5 min.)




Live pricePrice per Share (EOD)
$1.13
Intrinsic Value Per Share
$-3.98 - $1.87
Total Value Per Share
$-3.30 - $2.55

2.2. Growth of Akari Therapeutics PLC (5 min.)




Is Akari Therapeutics PLC growing?

Current yearPrevious yearGrowGrow %
How rich?$21.7m-$307.3k$8.7m103.7%

How much money is Akari Therapeutics PLC making?

Current yearPrevious yearGrowGrow %
Making money-$4.4m-$3.8m-$588.7k-13.1%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Akari Therapeutics PLC (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#502 / 872

Most Revenue
#767 / 872

Most Profit
#395 / 872

Most Efficient
#260 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Akari Therapeutics PLC?

Welcome investor! Akari Therapeutics PLC's management wants to use your money to grow the business. In return you get a share of Akari Therapeutics PLC.

First you should know what it really means to hold a share of Akari Therapeutics PLC. And how you can make/lose money.

Speculation

The Price per Share of Akari Therapeutics PLC is $1.1307. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Akari Therapeutics PLC.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Akari Therapeutics PLC, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.68. Based on the TTM, the Book Value Change Per Share is $0.20 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Akari Therapeutics PLC.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.12-10.2%-0.11-9.7%-0.11-9.7%-0.10-8.8%-0.12-10.3%-0.17-15.4%
Usd Book Value Change Per Share0.6859.7%0.2017.4%-0.10-9.2%0.021.8%0.032.7%0.011.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.6859.7%0.2017.4%-0.10-9.2%0.021.8%0.032.7%0.011.3%
Usd Price Per Share1.24-2.03-2.28-1.62-1.70-4.02-
Price to Earnings Ratio-2.69--1,078.60--4.96--361.88--217.85--111.06-
Price-to-Total Gains Ratio1.84--150.81--20.35--67.24--34.11-1.36-
Price to Book Ratio1.83-720.82--252.08-158.26-100.54-56.71-
Price-to-Total Gains Ratio1.84--150.81--20.35--67.24--34.11-1.36-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.1307
Number of shares884
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.200.03
Usd Total Gains Per Share0.200.03
Gains per Quarter (884 shares)173.7627.38
Gains per Year (884 shares)695.05109.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
106956850110100
20139013800219210
30208520750329320
40278027700438430
50347534650548540
60417041600657650
70486548550767760
80556055500876870
90625562450986980
10069516940010951090

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%4.036.00.010.0%4.038.00.09.5%
Book Value Change Per Share2.02.00.050.0%3.07.02.025.0%8.010.02.040.0%16.022.02.040.0%17.023.02.040.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.042.00.0%
Total Gains per Share2.02.00.050.0%3.07.02.025.0%8.010.02.040.0%16.022.02.040.0%17.023.02.040.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Akari Therapeutics PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.6750.197+244%-0.104+115%0.020+3237%0.031+2081%0.015+4439%
Book Value Per Share--0.6760.088+666%-0.010+101%0.082+719%0.133+407%0.366+85%
Current Ratio--0.1600.294-46%0.965-83%1.133-86%1.626-90%2.172-93%
Debt To Asset Ratio--0.5731.578-64%1.260-55%1.095-48%0.856-33%0.670-14%
Debt To Equity Ratio--1.3430.654+105%0.470+186%1.443-7%1.392-3%1.307+3%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--13267736.00016260747303.515-100%72105574.000-82%5452282236.055-100%3296737365.233-100%1758708642.967-99%
Eps---0.115-0.110-4%-0.109-5%-0.099-14%-0.116+1%-0.174+51%
Ev To Ebitda Ratio---0.909-3.714+309%-4.411+385%-3.009+231%-6.396+604%33.540-103%
Free Cash Flow Per Share---0.067-0.066-1%-0.106+58%-0.092+38%-0.107+60%-0.133+99%
Free Cash Flow To Equity Per Share---0.0010.007-107%-0.067+12551%-0.046+8681%-0.002+247%0.025-102%
Gross Profit Margin--1.0001.0000%1.166-14%1.046-4%1.027-3%1.014-1%
Intrinsic Value_10Y_max--1.874----------
Intrinsic Value_10Y_min---3.978----------
Intrinsic Value_1Y_max---0.289----------
Intrinsic Value_1Y_min---0.512----------
Intrinsic Value_3Y_max---0.504----------
Intrinsic Value_3Y_min---1.450----------
Intrinsic Value_5Y_max---0.282----------
Intrinsic Value_5Y_min---2.282----------
Market Cap36381855.480-10%39898736.00016277434303.515-100%73241530.500-46%5456342816.055-99%3297085315.033-99%1750441294.267-98%
Net Profit Margin----0%-0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%-0%
Pb Ratio1.673-10%1.835720.816-100%-252.079+13839%158.264-99%100.538-98%56.712-97%
Pe Ratio-2.455+9%-2.692-1078.600+39964%-4.959+84%-361.877+13342%-217.847+7992%-111.061+4025%
Price Per Share1.131-10%1.2402.028-39%2.276-46%1.625-24%1.698-27%4.016-69%
Price To Free Cash Flow Ratio-4.230+9%-4.639-1915.621+41190%-4147.165+89290%-2208.150+47496%-1327.188+28507%-662.738+14185%
Price To Total Gains Ratio1.674-10%1.836-150.806+8314%-20.350+1208%-67.238+3762%-34.109+1958%1.362+35%
Quick Ratio--0.1230.209-41%0.814-85%0.959-87%1.409-91%2.246-95%
Return On Assets---0.073-0.674+827%-0.998+1273%-0.629+765%-0.549+655%-0.425+485%
Return On Equity---0.170-0.085-50%-0.270+58%-0.448+163%-0.702+312%-0.694+307%
Total Gains Per Share--0.6750.197+244%-0.104+115%0.020+3237%0.031+2081%0.015+4439%
Usd Book Value--21746000.0008394500.000+159%-307385.750+101%4505017.333+383%5400747.450+303%12319302.525+77%
Usd Book Value Change Per Share--0.6750.197+244%-0.104+115%0.020+3237%0.031+2081%0.015+4439%
Usd Book Value Per Share--0.6760.088+666%-0.010+101%0.082+719%0.133+407%0.366+85%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--13267736.00016260747303.515-100%72105574.000-82%5452282236.055-100%3296737365.233-100%1758708642.967-99%
Usd Eps---0.115-0.110-4%-0.109-5%-0.099-14%-0.116+1%-0.174+51%
Usd Free Cash Flow---2150000.000-2664500.000+24%-3404920.075+58%-3144940.913+46%-3542309.098+65%-4329121.588+101%
Usd Free Cash Flow Per Share---0.067-0.066-1%-0.106+58%-0.092+38%-0.107+60%-0.133+99%
Usd Free Cash Flow To Equity Per Share---0.0010.007-107%-0.067+12551%-0.046+8681%-0.002+247%0.025-102%
Usd Market Cap36381855.480-10%39898736.00016277434303.515-100%73241530.500-46%5456342816.055-99%3297085315.033-99%1750441294.267-98%
Usd Price Per Share1.131-10%1.2402.028-39%2.276-46%1.625-24%1.698-27%4.016-69%
Usd Profit---3705000.000-4482500.000+21%-3893750.250+5%-3744952.583+1%-4049858.100+9%-5315111.250+43%
Usd Revenue----0%-0%-0%-0%-0%
Usd Total Gains Per Share--0.6750.197+244%-0.104+115%0.020+3237%0.031+2081%0.015+4439%
 EOD+2 -6MRQTTM+15 -17YOY+19 -143Y+21 -125Y+23 -1010Y+19 -14

3.3 Fundamental Score

Let's check the fundamental score of Akari Therapeutics PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.455
Price to Book Ratio (EOD)Between0-11.673
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.123
Current Ratio (MRQ)Greater than10.160
Debt to Asset Ratio (MRQ)Less than10.573
Debt to Equity Ratio (MRQ)Less than11.343
Return on Equity (MRQ)Greater than0.15-0.170
Return on Assets (MRQ)Greater than0.05-0.073
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Akari Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.140
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Akari Therapeutics PLC

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2025-07-10 20:12:07.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Akari Therapeutics PLC earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Akari Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--93.6%+93.6%
TTM--140.9%+140.9%
YOY--197.6%+197.6%
3Y--248.5%+248.5%
5Y--343.4%+343.4%
10Y--496.2%+496.2%
4.3.1.2. Return on Assets

Shows how efficient Akari Therapeutics PLC is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • -7.3% Return on Assets means that Akari Therapeutics PLC generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Akari Therapeutics PLC:

  • The MRQ is -7.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -67.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.3%TTM-67.4%+60.1%
TTM-67.4%YOY-99.8%+32.4%
TTM-67.4%5Y-54.9%-12.5%
5Y-54.9%10Y-42.5%-12.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.3%-11.6%+4.3%
TTM-67.4%-11.6%-55.8%
YOY-99.8%-11.4%-88.4%
3Y-62.9%-11.8%-51.1%
5Y-54.9%-12.0%-42.9%
10Y-42.5%-13.7%-28.8%
4.3.1.3. Return on Equity

Shows how efficient Akari Therapeutics PLC is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • -17.0% Return on Equity means Akari Therapeutics PLC generated $-0.17 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Akari Therapeutics PLC:

  • The MRQ is -17.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.0%TTM-8.5%-8.5%
TTM-8.5%YOY-27.0%+18.5%
TTM-8.5%5Y-70.2%+61.7%
5Y-70.2%10Y-69.4%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.0%-13.5%-3.5%
TTM-8.5%-14.9%+6.4%
YOY-27.0%-14.6%-12.4%
3Y-44.8%-16.8%-28.0%
5Y-70.2%-17.5%-52.7%
10Y-69.4%-19.9%-49.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Akari Therapeutics PLC.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Akari Therapeutics PLC is operating .

  • Measures how much profit Akari Therapeutics PLC makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Akari Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--232.5%+232.5%
TTM--250.5%+250.5%
YOY--209.2%+209.2%
3Y--234.1%+234.1%
5Y--346.1%+346.1%
10Y--477.5%+477.5%
4.3.2.2. Operating Ratio

Measures how efficient Akari Therapeutics PLC is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.111-2.111
TTM-2.694-2.694
YOY-3.096-3.096
3Y-3.652-3.652
5Y-4.745-4.745
10Y-6.614-6.614
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Akari Therapeutics PLC.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Akari Therapeutics PLC is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.16 means the company has $0.16 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 0.160. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.294. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.160TTM0.294-0.134
TTM0.294YOY0.965-0.671
TTM0.2945Y1.626-1.332
5Y1.62610Y2.172-0.546
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1603.661-3.501
TTM0.2943.846-3.552
YOY0.9654.140-3.175
3Y1.1334.688-3.555
5Y1.6265.746-4.120
10Y2.1726.147-3.975
4.4.3.2. Quick Ratio

Measures if Akari Therapeutics PLC is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • A Quick Ratio of 0.12 means the company can pay off $0.12 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 0.123. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.209. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.123TTM0.209-0.086
TTM0.209YOY0.814-0.605
TTM0.2095Y1.409-1.199
5Y1.40910Y2.246-0.838
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1232.848-2.725
TTM0.2093.169-2.960
YOY0.8143.786-2.972
3Y0.9594.311-3.352
5Y1.4095.703-4.294
10Y2.2466.368-4.122
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Akari Therapeutics PLC.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Akari Therapeutics PLC assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Akari Therapeutics PLC to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.57 means that Akari Therapeutics PLC assets are financed with 57.3% credit (debt) and the remaining percentage (100% - 57.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 0.573. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 1.578. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ0.573TTM1.578-1.005
TTM1.578YOY1.260+0.318
TTM1.5785Y0.856+0.722
5Y0.85610Y0.670+0.185
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5730.329+0.244
TTM1.5780.349+1.229
YOY1.2600.331+0.929
3Y1.0950.340+0.755
5Y0.8560.349+0.507
10Y0.6700.379+0.291
4.5.4.2. Debt to Equity Ratio

Measures if Akari Therapeutics PLC is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • A Debt to Equity ratio of 134.3% means that company has $1.34 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 1.343. The company is able to pay all its debts with equity. +1
  • The TTM is 0.654. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.343TTM0.654+0.689
TTM0.654YOY0.470+0.184
TTM0.6545Y1.392-0.737
5Y1.39210Y1.307+0.085
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3430.379+0.964
TTM0.6540.437+0.217
YOY0.4700.414+0.056
3Y1.4430.450+0.993
5Y1.3920.464+0.928
10Y1.3070.515+0.792
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Akari Therapeutics PLC generates.

  • Above 15 is considered overpriced but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • A PE ratio of -2.69 means the investor is paying $-2.69 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Akari Therapeutics PLC:

  • The EOD is -2.455. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.692. Based on the earnings, the company is expensive. -2
  • The TTM is -1,078.600. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.455MRQ-2.692+0.237
MRQ-2.692TTM-1,078.600+1,075.908
TTM-1,078.600YOY-4.959-1,073.642
TTM-1,078.6005Y-217.847-860.754
5Y-217.84710Y-111.061-106.786
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.455-2.356-0.099
MRQ-2.692-2.077-0.615
TTM-1,078.600-2.574-1,076.026
YOY-4.959-3.760-1.199
3Y-361.877-3.773-358.104
5Y-217.847-6.193-211.654
10Y-111.061-6.876-104.185
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Akari Therapeutics PLC:

  • The EOD is -4.230. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.639. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1,915.621. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.230MRQ-4.639+0.409
MRQ-4.639TTM-1,915.621+1,910.982
TTM-1,915.621YOY-4,147.165+2,231.543
TTM-1,915.6215Y-1,327.188-588.433
5Y-1,327.18810Y-662.738-664.450
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.230-3.246-0.984
MRQ-4.639-2.705-1.934
TTM-1,915.621-3.704-1,911.917
YOY-4,147.165-4.402-4,142.763
3Y-2,208.150-5.070-2,203.080
5Y-1,327.188-8.477-1,318.711
10Y-662.738-9.305-653.433
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Akari Therapeutics PLC is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.83 means the investor is paying $1.83 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Akari Therapeutics PLC:

  • The EOD is 1.673. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.835. Based on the equity, the company is underpriced. +1
  • The TTM is 720.816. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.673MRQ1.835-0.162
MRQ1.835TTM720.816-718.982
TTM720.816YOY-252.079+972.896
TTM720.8165Y100.538+620.279
5Y100.53810Y56.712+43.825
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.6732.038-0.365
MRQ1.8351.843-0.008
TTM720.8162.125+718.691
YOY-252.0792.442-254.521
3Y158.2642.492+155.772
5Y100.5383.652+96.886
10Y56.7124.311+52.401
4.6.2. Total Gains per Share

2.4. Latest News of Akari Therapeutics PLC

Does Akari Therapeutics PLC still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Akari Therapeutics PLC to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-07-01
23:57
Akari Therapeutics shareholders approve equity plan increase and director electionsRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Akari Therapeutics PLC.

4.8.1. Institutions holding Akari Therapeutics PLC

Institutions are holding 0.983% of the shares of Akari Therapeutics PLC.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Palo Alto Investors, LLC0.45380.034514602400
2025-03-31Omnia Family Wealth, LLC0.27230.04558762800
2025-03-31HPM Partners LLC0.07350.00012364300
2025-03-31Cresset Asset Management, LLC0.05720.00011840800
2025-03-31Renaissance Technologies Corp0.0571018384-5081-21.6535
2025-03-31Accent Capital Management LLC0.03110.00721000000
2025-03-31Bank of America Corp0.0005015000
2025-03-31Royal Bank of Canada0.000301001000
2025-03-31Truvestments Capital LLC0.000205000
2025-03-31Morgan Stanley - Brokerage Accounts00600
2025-03-31Cornerstone Planning Group LLC00500
2024-12-31Citadel Advisors Llc000-33260-100
2025-03-31UBS Group AG000-194-100
2025-03-31SBI Securities Co Ltd000-5-100
2025-03-31Advisor Group Holdings, Inc.000-100-100
Total 0.9460.0874304398-38540-12.7%

4.9.2. Funds holding Akari Therapeutics PLC

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-05-31LUX IM Global Medtech HX0.03190.00871026400
2025-03-31RiverNorth Marketplace Lending Corp0.00340.0024110300
2025-03-31RiverNorth Opportunities0.00160.000250900
Total 0.03690.01131187600.0%

5.3. Insider Transactions

Insiders are holding 34.696% of the shares of Akari Therapeutics PLC.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-06-24Abizer GaslightwalaBUY52031.16
2025-06-23Abizer GaslightwalaBUY9431.15
2025-06-20Abizer GaslightwalaBUY100001.2
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets50,959
Total Liabilities29,213
Total Stockholder Equity21,746
 As reported
Total Liabilities 29,213
Total Stockholder Equity+ 21,746
Total Assets = 50,959

Assets

Total Assets50,959
Total Current Assets3,349
Long-term Assets47,610
Total Current Assets
Cash And Cash Equivalents 2,582
Other Current Assets 767
Total Current Assets  (as reported)3,349
Total Current Assets  (calculated)3,349
+/-0
Long-term Assets
Goodwill 8,430
Intangible Assets 39,180
Long-term Assets  (as reported)47,610
Long-term Assets  (calculated)47,610
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities20,907
Long-term Liabilities8,306
Total Stockholder Equity21,746
Total Current Liabilities
Short-term Debt 1,846
Short Long Term Debt 1,846
Accounts payable 13,067
Other Current Liabilities 5,994
Total Current Liabilities  (as reported)20,907
Total Current Liabilities  (calculated)22,753
+/- 1,846
Long-term Liabilities
Long-term Liabilities Other 266
Long-term Liabilities  (as reported)8,306
Long-term Liabilities  (calculated)266
+/- 8,040
Total Stockholder Equity
Common Stock5,776
Retained Earnings -250,957
Accumulated Other Comprehensive Income -773
Other Stockholders Equity 267,700
Total Stockholder Equity (as reported)21,746
Total Stockholder Equity (calculated)21,746
+/-0
Other
Capital Stock5,776
Cash and Short Term Investments 2,582
Common Stock Shares Outstanding 27
Liabilities and Stockholders Equity 50,959
Net Debt -736
Net Invested Capital 23,592
Net Working Capital -17,558
Short Long Term Debt Total 1,846



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-31
> Total Assets 
0
0
0
6,480
4,317
2,960
79,174
69,894
62,959
57,633
52,070
45,874
36,517
32,053
22,427
29,050
25,496
17,120
12,627
16,452
8,810
5,151
10,670
10,307
9,969
14,452
13,694
14,605
7,840
4,830
14,719
11,648
19,455
11,371
13,832
13,832
8,013
8,013
4,355
4,355
2,772
5,076
2,734
50,562
50,959
50,95950,5622,7345,0762,7724,3554,3558,0138,01313,83213,83211,37119,45511,64814,7194,8307,84014,60513,69414,4529,96910,30710,6705,1518,81016,45212,62717,12025,49629,05022,42732,05336,51745,87452,07057,63362,95969,89479,1742,9604,3176,480000
   > Total Current Assets 
554
0
0
6,431
4,273
2,920
78,939
69,658
62,693
57,374
51,824
45,634
36,282
31,805
22,194
28,813
25,266
16,523
12,041
16,399
8,613
5,091
10,632
10,272
9,939
14,426
13,667
14,578
7,813
4,804
14,695
11,625
19,433
11,352
13,815
13,815
13,250
7,997
4,341
4,341
2,772
5,076
2,734
2,952
3,349
3,3492,9522,7345,0762,7724,3414,3417,99713,25013,81513,81511,35219,43311,62514,6954,8047,81314,57813,66714,4269,93910,27210,6325,0918,61316,39912,04116,52325,26628,81322,19431,80536,28245,63451,82457,37462,69369,65878,9392,9204,2736,43100554
       Cash And Cash Equivalents 
-554
0
0
6,216
4,016
2,718
78,773
68,920
61,430
9,662
5,525
34,099
24,919
30,119
20,974
28,107
23,781
15,070
10,073
5,968
6,146
2,737
6,269
5,732
7,822
12,746
12,318
14,056
6,668
3,792
13,391
9,361
16,723
8,151
13,250
13,250
7,181
7,181
3,845
3,845
1,310
4,177
2,246
2,599
2,582
2,5822,5992,2464,1771,3103,8453,8457,1817,18113,25013,2508,15116,7239,36113,3913,7926,66814,05612,31812,7467,8225,7326,2692,7376,1465,96810,07315,07023,78128,10720,97430,11924,91934,0995,5259,66261,43068,92078,7732,7184,0166,21600-554
       Short-term Investments 
1,107
0
0
0
7
0
0
0
0
46,120
45,101
10,022
10,022
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000010,02210,02245,10146,120000070001,107
       Net Receivables 
0
0
0
73
115
60
10
10
11
11
11
0
0
0
0
0
0
0
0
10,431
10,431
2,903
2,903
4,540
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000004,5402,9032,90310,43110,4310000000011111110106011573000
       Other Current Assets 
0
0
0
8
130
142
166
728
1,253
1,581
1,187
1,513
1,341
1,686
1,220
706
1,485
1,453
1,967
2,008
2,468
2,354
1,461
713
2,117
1,679
1,349
522
1,145
1,012
1,304
2,264
2,711
3,201
565
565
817
817
496
496
1,462
899
488
201
767
7672014888991,4624964968178175655653,2012,7112,2641,3041,0121,1455221,3491,6792,1177131,4612,3542,4682,0081,9671,4531,4857061,2201,6861,3411,5131,1871,5811,2537281661421308000
   > Long-term Assets 
-554
0
0
49
44
40
235
235
266
259
246
240
235
248
233
237
229
596
586
53
197
60
38
35
30
26
27
27
26
26
24
23
21
19
17
17
-13,250
16
14
14
0
0
0
47,610
47,610
47,61047,610000141416-13,2501717192123242626272726303538601975358659622923723324823524024625926623523540444900-554
       Property Plant Equipment 
0
0
0
49
44
40
35
41
75
71
62
58
54
74
65
56
47
39
30
20
16
12
8
5
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000025812162030394756657454586271754135404449000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,430
8,430
8,4308,4300000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
58
52
49
46
43
39
39
32
26
39
40
36
35
33
33
31
29
30
28
26
27
27
26
26
24
23
21
19
17
17
16
16
14
14
0
0
0
39,180
39,180
39,18039,18000014141616171719212324262627272628302931333335364039263239394346495258000000
       Long-term Assets Other 
-554
0
0
0
10
0
142
142
142
142
142
142
142
142
142
142
142
521
522
522
148
17
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-13,250
0
0
0
0
0
0
0
0
00000000-13,2500000000000000017148522522521142142142142142142142142142142142010000-554
> Total Liabilities 
0
0
0
1,627
1,722
1,987
37,843
21,174
16,601
17,049
11,030
11,771
14,121
9,201
9,385
9,071
9,171
8,493
6,324
3,076
7,590
6,523
7,419
6,471
8,153
11,113
8,835
5,220
3,903
3,242
3,356
6,093
5,524
3,045
12,041
12,041
-1,791
5,232
4,584
4,584
6,325
8,779
9,428
28,333
29,213
29,21328,3339,4288,7796,3254,5844,5845,232-1,79112,04112,0413,0455,5246,0933,3563,2423,9035,2208,83511,1138,1536,4717,4196,5237,5903,0766,3248,4939,1719,0719,3859,20114,12111,77111,03017,04916,60121,17437,8431,9871,7221,627000
   > Total Current Liabilities 
0
0
0
1,359
910
960
37,797
21,125
16,549
16,994
10,975
11,715
14,064
9,143
9,332
9,023
9,077
8,280
6,149
3,076
7,590
6,523
7,419
5,456
8,153
11,113
8,835
5,220
3,903
3,242
3,356
6,093
5,524
3,045
12,041
12,041
5,232
5,232
4,584
4,584
6,325
8,779
9,428
19,910
20,907
20,90719,9109,4288,7796,3254,5844,5845,2325,23212,04112,0413,0455,5246,0933,3563,2423,9035,2208,83511,1138,1535,4567,4196,5237,5903,0766,1498,2809,0779,0239,3329,14314,06411,71510,97516,99416,54921,12537,7979609101,359000
       Short-term Debt 
0
0
0
1
0
0
3,031
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
1,000
0
1,846
1,84601,0001,00000000000000000000000000000000000003,031001000
       Short Long Term Debt 
0
0
0
534
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
1,000
3,260
1,846
1,8463,2601,0001,0000000000000000000000000000000000000000534000
       Accounts payable 
0
0
0
556
296
629
3,754
4,321
625
1,918
1,308
2,214
924
2,842
1,943
1,971
2,384
2,002
1,404
1,586
1,763
1,482
1,315
1,229
966
2,191
2,411
3,381
2,832
1,685
1,923
1,789
3,076
1,635
947
947
1,031
1,031
1,671
1,671
3,208
4,686
4,782
12,407
13,067
13,06712,4074,7824,6863,2081,6711,6711,0311,0319479471,6353,0761,7891,9231,6852,8323,3812,4112,1919661,2291,3151,4821,7631,5861,4042,0022,3841,9711,9432,8429242,2141,3081,9186254,3213,754629296556000
       Other Current Liabilities 
0
0
0
803
614
331
31,012
16,804
15,924
15,076
9,667
9,500
13,139
6,301
7,389
9,877
6,693
6,278
4,745
3,332
5,826
5,042
6,104
4,227
7,187
8,922
6,425
1,840
1,071
1,556
1,432
4,305
2,448
1,411
11,094
11,094
4,201
4,201
2,913
2,913
3,117
3,093
3,646
1,106
5,994
5,9941,1063,6463,0933,1172,9132,9134,2014,20111,09411,0941,4112,4484,3051,4321,5561,0711,8406,4258,9227,1874,2276,1045,0425,8263,3324,7456,2786,6939,8777,3896,30113,1399,5009,66715,07615,92416,80431,012331614803000
   > Long-term Liabilities 
0
0
0
268
812
1,027
46
49
52
55
56
56
57
58
53
48
94
213
175
0
0
0
1,015
1,015
0
0
0
0
0
1,685
1,789
1,789
3,076
1,635
0
0
-1,791
0
0
0
0
0
0
8,423
8,306
8,3068,423000000-1,791001,6353,0761,7891,7891,685000001,0151,01500017521394485358575656555249461,027812268000
       Other Liabilities 
0
0
0
49
0
1,027
46
49
52
55
55
56
57
58
53
48
94
213
175
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000017521394485358575655555249461,027049000
> Total Stockholder Equity
288
0
0
4,853
2,595
973
41,331
48,720
46,358
40,584
41,040
34,103
22,396
22,852
13,042
19,979
16,324
8,627
6,303
13,376
1,220
-1,372
3,250
3,836
1,816
3,339
4,858
9,384
3,937
1,588
11,363
5,555
13,931
8,326
1,791
1,791
1,791
2,781
-229
-229
-3,553
-3,703
-6,694
22,229
21,746
21,74622,229-6,694-3,703-3,553-229-2292,7811,7911,7911,7918,32613,9315,55511,3631,5883,9379,3844,8583,3391,8163,8363,250-1,3721,22013,3766,3038,62716,32419,97913,04222,85222,39634,10341,04040,58446,35848,72041,3319732,5954,85300288
   Common Stock
0
0
0
927
927
927
18,341
18,341
18,341
18,341
18,341
18,341
18,341
18,341
18,341
22,928
22,928
22,928
23,651
23,651
23,717
24,538
30,124
31,987
40,086
46,579
46,579
385
385
396
476
476
593
593
745
745
1,012
1,012
1,324
1,324
1,598
2,430
2,430
0
5,776
5,77602,4302,4301,5981,3241,3241,0121,01274574559359347647639638538546,57946,57940,08631,98730,12424,53823,71723,65123,65122,92822,92822,92818,34118,34118,34118,34118,34118,34118,34118,34118,341927927927000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
288
0
0
0
2
0
197
156
-36
-192
-341
-280
-325
-374
-288
-236
-203
-231
-296
-12,246
-245
-405
-402
-12,242
-572
-618
-621
-648
-342
-420
-447
-541
-573
-622
51,423
51,423
1,791
-826
51,154
51,154
51,433
-749
-926
0
-773
-7730-926-74951,43351,15451,154-8261,79151,42351,423-622-573-541-447-420-342-648-621-618-572-12,242-402-405-245-12,246-296-231-203-236-288-374-325-280-341-192-3615619702000288
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
106,239
106,616
107,097
107,961
109,560
110,499
109,596
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000109,596110,499109,560107,961107,097106,616106,239000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
2,445
35,102
34,224
86,062
87,019
87,836
88,668
89,692
90,979
91,902
92,727
93,208
104,800
105,276
105,627
106,239
106,616
107,097
107,961
109,560
137,397
109,596
112,989
113,070
191,928
139,820
141,883
153,057
153,131
218,792
166,721
167,076
167,076
170,852
170,852
174,754
174,754
176,443
235,201
235,282
0
267,700
267,7000235,282235,201176,443174,754174,754170,852170,852167,076167,076166,721218,792153,131153,057141,883139,820191,928113,070112,989109,596137,397109,560107,961107,097106,616106,239105,627105,276104,80093,20892,72791,90290,97989,69288,66887,83687,01986,06234,22435,1022,445000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-21,643
Operating Income-21,643-21,643
 
Operating Expense (+$)
Research Development6,983
Selling General Administrative9,664
Selling And Marketing Expenses0
Operating Expense21,64316,647
 
Net Interest Income (+$)
Interest Income8
Interest Expense-244
Other Finance Cost-0
Net Interest Income-236
 
Pretax Income (+$)
Operating Income-21,643
Net Interest Income-236
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-19,791-23,495
EBIT - interestExpense = -20,279
-19,791
-19,547
Interest Expense244
Earnings Before Interest and Taxes (EBIT)-20,035-19,547
Earnings Before Interest and Taxes (EBITDA)-21,643
 
After tax Income (+$)
Income Before Tax-19,791
Tax Provision-0
Net Income From Continuing Ops-19,791-19,791
Net Income-19,791
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net1,852236
 

Technical Analysis of Akari Therapeutics PLC
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Akari Therapeutics PLC. The general trend of Akari Therapeutics PLC is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Akari Therapeutics PLC's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Akari Therapeutics PLC Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Akari Therapeutics PLC.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.1801 < 1.201 < 1.42.

The bearish price targets are: 1.11 > 1.1 > 1.08.

Know someone who trades $AKTX? Share this with them.👇

Akari Therapeutics PLC Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Akari Therapeutics PLC. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Akari Therapeutics PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Akari Therapeutics PLC.

Akari Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) ChartAkari Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Akari Therapeutics PLC. The current adx is .

Akari Therapeutics PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Akari Therapeutics PLC.

Akari Therapeutics PLC Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Akari Therapeutics PLC.

Akari Therapeutics PLC Daily Relative Strength Index (RSI) ChartAkari Therapeutics PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Akari Therapeutics PLC.

Akari Therapeutics PLC Daily Stochastic Oscillator ChartAkari Therapeutics PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Akari Therapeutics PLC.

Akari Therapeutics PLC Daily Commodity Channel Index (CCI) ChartAkari Therapeutics PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Akari Therapeutics PLC.

Akari Therapeutics PLC Daily Chande Momentum Oscillator (CMO) ChartAkari Therapeutics PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Akari Therapeutics PLC.

Akari Therapeutics PLC Daily Williams %R ChartAkari Therapeutics PLC Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Akari Therapeutics PLC.

Akari Therapeutics PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Akari Therapeutics PLC.

Akari Therapeutics PLC Daily Average True Range (ATR) ChartAkari Therapeutics PLC Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Akari Therapeutics PLC.

Akari Therapeutics PLC Daily On-Balance Volume (OBV) ChartAkari Therapeutics PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Akari Therapeutics PLC.

Akari Therapeutics PLC Daily Money Flow Index (MFI) ChartAkari Therapeutics PLC Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Akari Therapeutics PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-19MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-31MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Akari Therapeutics PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Akari Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.140
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Akari Therapeutics PLC with someone you think should read this too:
  • Are you bullish or bearish on Akari Therapeutics PLC? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Akari Therapeutics PLC? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Akari Therapeutics PLC

I send you an email if I find something interesting about Akari Therapeutics PLC.


Comments

How you think about this?

Leave a comment

Stay informed about Akari Therapeutics PLC.

Receive notifications about Akari Therapeutics PLC in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.